Pluristem Therapeutics

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.

Pluri CEO Issues Shareholder Update

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from Pluristem Therapeutics Inc. Nasdaq: PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harnessed for a range of fields beyond medicine, providing solutions for various areas of the life sciences. As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol “PLUR,” CUSIP number 72942G 104.

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture.  The 240-subject study did not meet the primary endpoint, the Short.

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET  at Nasdaq MarketSite in Times Square, New York

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

HAIFA, Israel, March 23, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company developing novel cell therapies, today announced positive final results from its innovative hematology Phase I study to evaluate the safety and exploratory efficacy of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following HCT.

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel's largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat.

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.

Pluristem CEO Issues Shareholder Update

HAIFA, Israel, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”) and Israel's largest food producer Tnuva Group (“Tnuva”) announced today the closing of its landmark collaboration to develop, manufacture and commercialize cell-based products for the food industry. The collaboration is a major step forward to bringing sustainable cultured food to everyday consumers globally.

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Didi Global

Farmmi

Phunware Inc

Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy as January Ends? 4 to Watch

Dogness

Reviva Pharmaceuticals

Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 For Your List in January

Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry.  Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products.

Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform

HAIFA, Israel, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem” or “the Company”), a leading biotechnology company, and Tnuva Group (“Tnuva Group" or “Tnuva”), Israel's largest food producer, (together, “Parties”) today announced the launch of an innovative collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry. The collaboration started with the incorporation of a new company (“NewCo”), that will receive exclusive, global, royalty bearing licensing rights to use Pluristem's proprietary technology, intellectual property and knowhow, to be used in the field of cultured meat.

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS

HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLX-PAD cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The analysis is based on 89 patients enrolled in two Phase II studies in the U.S. (the “U.S. study”) and in Europe and Israel (collectively, the “EU study” and together with the U.S. study, the “Studies”).

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Having recruited patients in the U.S., Europe and Israel, t he Company anticipates topline results in the third calendar quarter of 2022

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Following achievements met in the project, the IIA to provide an additional budget to advance work of CRISPR-IL National Consortium, in which Pluristem is leading the Pharma group, and working with other industry and academic leaders in genome editing Following achievements met in the project, the IIA to provide an additional budget to advance work of CRISPR-IL National Consortium, in which Pluristem is leading the Pharma group, and working with other industry and academic leaders in genome editing

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform

HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market.

Pluristem Appoints Prof. Varda Shalev MD and Mr.

HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout. The Company's COVID-19 program included over 100 patients across two Phase II studies in the U.S., Europe and Israel, and in compassionate use and expanded access programs in the U.S. and Israel. The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristem's PLX cells as a treatment for severe COVID-19 cases complicated by ARDS.

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 62,000 shares of Pluristem Therapeutics Inc.

Cathie Wood's ARK Invest Sells Over 60,000 Shares of Pluristem Therapeutics

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 194,000 shares of Pluristem Therapeutics Inc.

Cathie Wood's ARK Invest Sells 194,000 Shares of Pluristem Therapeutics

Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursement reflects that Pluristem has achieved a key milestone in a previously announced €50 million non-dilutive financing agreement.

Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank

Pluristem Therapeutics Inc (NASDAQ: PSTI) has reported positive topline results from Phase 1 study evaluating intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT). The results demonstrate that PLX-R18 has the potential to stimulate the implanted hematopoietic cells to realize their therapeutic potential and generate improved blood counts over the long term in all three blood cell lineages at once.

Pluristem Stock Is Trading Higher As PLX-R18 Shows Regenerative Potential In Patients After Bone Marrow Transplant

The stock price of Pluristem Therapeutics Inc. (NASDAQ: PSTI) increased from $4.52 to over $4.90 pre-market. This is why it happened.

News for Pluristem Therapeutics Stock (PSTI)